Pharmaceuticals Market Research Reports & Industry Analysis

Publications found: 36,694

Sort by:

Acne Drugs Market Size, Share & Trends Analysis Report By Type, By Therapeutic Class (Retinoid, Antibiotic, Combination), By Mode of Administration (Injectable, Topical, Oral), And Segment Forecasts, 2018 - 2025

US$ 5,950.00

The global acne drugs market size is expected to reach USD 5.9 billion by 2025, according to a new report by Grand ... -stage pipeline products indicate a promising future for the global acne drugs market. Further key findings from the report suggest: By type, inflammatory ...

August 2018 83 pages

Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant), By Major Markets, Vendor Landscape, And Segment Forecasts, 2018 - 2023

US$ 5,950.00

The global sickle cell disease treatment market size is expected to reach USD 5.5 billion by 2023, according to a new report by ... favorable government initiatives are anticipated to drive the market. Currently available treatments for sickle cell disease (SCD) usually provide symptomatic relief and palliative ...

August 2018 70 pages

Orphan Drug Market - Forecasts from 2018 to 2023

US$ 3,950.00

The orphan drug market is projected to grow at a CAGR of 10.94% to reach US$285.799 billion in 2023 from US$153.275 billion in 2017. During the forecast period, prescription sales ...

August 2018 108 pages

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape Develop ...

August 2018 103 pages

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development ...

August 2018 127 pages

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2018

US$ 3,500.00

... Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 67 pages

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2018

US$ 3,500.00

... key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development ...

August 2018 59 pages

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Pipeline Review, H2 2018

US$ 3,500.00

... . It also reviews key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics development with respective active ...

August 2018 40 pages

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) development ...

August 2018 52 pages

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape Develop and design ...

August 2018 119 pages

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Pipeline Review, H2 2018

US$ 3,500.00

... Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 84 pages

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H2 2018

US$ 3,500.00

... also reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics development with ...

August 2018 69 pages

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2018

US$ 3,500.00

... RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 53 pages

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2018

US$ 3,500.00

... Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 73 pages

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Pipeline Review, H2 2018

US$ 3,500.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) development landscape Develop ...

August 2018 63 pages

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) - Pipeline Review, H2 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) development landscape Develop and design ...

August 2018 45 pages

Myelodysplastic Syndrome (MDS) Drugs Market Size, Share & Trends Analysis By Therapeutic Class (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics), And Segment Forecasts, 2016 - 2022

US$ 5,950.00

The global myelodysplastic syndrome (MDS) drugs market size is expected to reach USD 2.4 billion by 2022, according to a new report by ... in U.S. are living with myelodysplastic syndrome, with approximately 10,000-15,000 new cases being reported annually U.S. dominated the global MDS drugs market with more than ...

August 2018 67 pages

Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report By Treatment Class (Chemotherapy, Immunotherapy), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023

US$ 5,950.00

The global urothelial cancer drugs market size is expected to reach USD 3.6 billion by 2023, as per a new report by Grand ... Availability of novel drugs, presence of a strong pipeline, rising disease incidence, unhealthy lifestyle, and increasing awareness are driving this market. Urothelial cancer is the ninth ...

August 2018 86 pages

Visceral Pain - Pipeline Review, H2 2018

US$ 2,000.00

... . The Visceral Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

August 2018 113 pages

Trigeminal Neuralgia - Pipeline Review, H2 2018

US$ 2,000.00

... Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

August 2018 52 pages

Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2018

US$ 2,000.00

... . The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

August 2018 48 pages

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape Develop ...

August 2018 64 pages

Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2018

US$ 3,500.00

... Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 48 pages

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2018

US$ 3,500.00

... Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 50 pages

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2018

US$ 3,500.00

... Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 78 pages

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2018

US$ 3,500.00

... Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 55 pages

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H2 2018

US$ 3,500.00

... Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 48 pages

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2018

US$ 3,500.00

... C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 61 pages

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape ...

August 2018 52 pages

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H2 2018

US$ 3,500.00

... C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 67 pages

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2018

US$ 3,500.00

... T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 75 pages

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2018

US$ 3,500.00

... Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 61 pages

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H2 2018

US$ 3,500.00

... reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 49 pages

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape Develop and design ...

August 2018 113 pages

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) development landscape Develop ...

August 2018 38 pages

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) development landscape Develop ...

August 2018 63 pages

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H2 2018

US$ 3,500.00

... key players involved in Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics development with respective active ...

August 2018 56 pages

RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Pipeline Review, H2 2018

US$ 3,500.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) development landscape Develop and ...

August 2018 56 pages

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape Develop ...

August 2018 74 pages

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Pipeline Review, H2 2018

US$ 3,500.00

... Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

August 2018 52 pages

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) development ...

August 2018 59 pages

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H2 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape Develop ...

August 2018 62 pages

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2018

US$ 3,500.00

... also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with ...

August 2018 111 pages

Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023

US$ 2,000.00

... “Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023”, the Global Antibody Drug Conjugates ... and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information ...

August 2018 110 pages

Aspergillosis Drug Development Pipeline Study, H2 2018

US$ 1,080.00

Aspergillosis Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Aspergillosis pipeline products. DISEASE OVERVIEW Aspergillus is a general fungus type that causes ...

August 2018 90 pages

Burkholderia pseudomallei Infection Drug Development Pipeline Study, H2 2018

US$ 1,080.00

... is the main challenge in detecting and treating Burkholderia Infections disease. Individuals with low immunity levels and ... Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Burkholderia ...

August 2018 45 pages

Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018

US$ 1,080.00

Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chagas Disease (American trypanosomiasis) pipeline products. DISEASE OVERVIEW Chagas disease, also known as American Trypanosomiasis, is one of the ...

August 2018 70 pages

Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018

US$ 1,080.00

Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chikungunya (CHIKV) Infection pipeline products. DISEASE OVERVIEW Chikungunya fever is a viral fever, caused ...

August 2018 90 pages

Chlamydia Drug Development Pipeline Study, H2 2018

US$ 1,080.00

Chlamydia Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chlamydia pipeline products. DISEASE OVERVIEW Chlamydia infections are caused by Chlamydia trachomatis bacteria. Worldwide, the ...

August 2018 60 pages

Cryptosporidiosis (crypto) Drug Development Pipeline Study, H2 2018

US$ 1,080.00

Cryptosporidiosis (crypto) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Cryptosporidiosis (crypto) pipeline products. DISEASE OVERVIEW Cryptosporidium is one of the most widespread intestinal ...

August 2018 30 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

Discount Offer from GMD Research

Special Offer from MP Advisors

Special Offer on Therapy Class R...